E

Editas Medicine

D
EDIT
USD
-0.11
(-3.3537%)
Market Closed
88,901.00
Volume
-3.125
EPS
-
Div Yield
-1.360515
P/E
261,450,302.12
Market Cap
Today
-2.4615%
1 Week
9.122%
1 Month
-1.092%
6 Months
-44.239%
12 Months
-64.660%
Year To Date
-68.676%
All Time
0%

Title:
Editas Medicine

Sector:
Healthcare
Industry:
Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Do you need help or have a question?